What to Do When First-Line Therapy Fails in Vitamin D-Dependent Rickets Type 2A (VDDR2A)

Vitamin D-dependent rickets type 2A (VDDR2A) is caused by mutations in the VDR gene that impair vitamin D receptor signaling. In a subset of affected patients, first-line treatment does not achieve the necessary metabolic targets, requiring a structured next-line approach.

Clinical scenario

Patients with VDDR2A carry VDR mutations that cause impaired vitamin D receptor signaling. Despite first-line calcium and active vitamin D therapy, key metabolic targets have not been reached and treatment escalation is required.

First-line failure condition

Prior therapy — high-dose oral calcium, intravenous calcium infusions (when oral calcium was insufficient), and active vitamin D analogues including calcitriol, alphacalcidiol, vitamin D3, vitamin D2, calcidiol, plus supplemental oral calcium — did not achieve:

Normocalcemia
Normalization of PTH levels
Normal bone mineral density

Next-line approach (partial overview)

When these targets remain unmet, a prolonged course of intravenous calcium in combination with active vitamin D may be indicated — with the aim of eventually transitioning to oral supplementation that maintains normocalcemia. The complete regimen, monitoring schedule, and transition criteria are detailed in the full structured protocol.

Treatment goals

Normocalcemia
Adequate skeletal mineralization

Instant Access to Structured Evidence-Based Regimens

References

Vitamin D-dependent rickets type 2A (VDDR2A) is due to mutations in VDR resulting in impaired signaling of the vitamin D receptor.

Therefore, these patients may require intravenous calcium infusions (1000 mg of elemental calcium per day, given over 12 h) over many months until oral supplementation with calcium salts in conjunction with active vitamin D, allows for maintenance of both normocalcemia and adequate skeletal mineralization.

DOI: 10.1007/s00467-022-05505-5

View source ↗